IDEAYA Biosciences (NASDAQ:IDYA) Receives “Overweight” Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of IDEAYA Biosciences (NASDAQ:IDYA) in a research note published on Tuesday,Benzinga reports.

Several other research analysts have also recently issued reports on the company. Stifel Nicolaus increased their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Wedbush reiterated an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $53.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Finally, UBS Group began coverage on IDEAYA Biosciences in a research note on Thursday, October 24th. They set a “buy” rating and a $50.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Stock Down 3.1 %

Shares of IDEAYA Biosciences stock opened at $24.79 on Tuesday. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -10.64 and a beta of 0.79. IDEAYA Biosciences has a 52-week low of $24.48 and a 52-week high of $47.74. The company’s 50-day simple moving average is $28.38 and its 200-day simple moving average is $34.10.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same period last year, the firm posted ($0.46) EPS. Equities research analysts anticipate that IDEAYA Biosciences will post -2.45 EPS for the current year.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP raised its holdings in IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the last quarter. Covestor Ltd raised its stake in shares of IDEAYA Biosciences by 23,050.0% in the 3rd quarter. Covestor Ltd now owns 926 shares of the company’s stock valued at $29,000 after acquiring an additional 922 shares during the period. Quest Partners LLC acquired a new stake in IDEAYA Biosciences in the 2nd quarter valued at $41,000. US Bancorp DE raised its position in IDEAYA Biosciences by 67.2% in the third quarter. US Bancorp DE now owns 1,714 shares of the company’s stock valued at $54,000 after purchasing an additional 689 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in IDEAYA Biosciences by 637.9% in the second quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company’s stock valued at $68,000 after purchasing an additional 1,684 shares during the period. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.